Mazdutide: molecular data, studies & sources

Molecular formula, weight & structure

Molecular formula (MF)

C207H317N45O65

Molecular weight (MW)

4476 g/mol

PubChem compound ID

167312357

Record title

Mazdutide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 167312357 · retrieved 2026-09-21

US regulatory status & drug development

Drugs@FDA lists no NDA, BLA or ANDA with mazdutide as an active ingredient (names searched: MAZDUTIDE, LY3305677, IBI362; checked October 7, 2026). Research-labelled Mazdutide listings are not FDA-approved drugs.

An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Investigational INN; development codes LY3305677 and IBI362 also searched.

Source: Drugs@FDA via openFDA (active-ingredient search for MAZDUTIDE, LY3305677, IBI362) · checked 2026-10-07. openFDA data are not intended for clinical decisions.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Mazdutide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

40 registered studies matched, 24 currently active or recruiting, 1 with results posted on ClinicalTrials.gov.

By highest phase

Phase 4 · 5Phase 3 · 11Phase 2 · 12Phase 1 · 5Not applicable · 7

By registry status

Completed · 15Not Yet Recruiting · 12Recruiting · 9Active Not Recruiting · 3Unknown · 1

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Mazdutide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

1. Human study · PubMed trial index Compound given to participants

   Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

   Ji L, Jiang H, Bi Y et al. · The New England journal of medicine · 2025

   PMID 40421736 · DOI: 10.1056/NEJMoa2411528 · Registration NCT05607680

2. Human study · PubMed trial index Compound given to participants

   Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

   Zhang B, Cheng Z, Chen J et al. · Diabetes care · 2024

   PMID 37943529 · DOI: 10.2337/dc23-1287 · Registration NCT04965506

3. Human study · PubMed trial index Compound given to participants

   Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

   Guo L, Zhang B, Xue X et al. · Nature · 2026

   PMID 41407860 · DOI: 10.1038/s41586-025-10031-z · Registration NCT05606913

4. Human study · PubMed trial index Compound given to participants

   Mazdutide versus placebo in Chinese adults with type 2 diabetes.

   Zhu D, Zhao J, Cai H et al. · Nature · 2026

   PMID 41407859 · DOI: 10.1038/s41586-025-10026-w

5. Human study · PubMed trial index Compound given to participants

   A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

   Ji L, Jiang H, Cheng Z et al. · Nature communications · 2023

   PMID 38092790 · DOI: 10.1038/s41467-023-44067-4 · Registration NCT04904913

6. Human study · PubMed trial index Compound given to participants

   Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

   Gao L, Jiang H, Cai H et al. · JAMA · 2026

   PMID 42251595 · DOI: 10.1001/jama.2026.8142 · Registration NCT06164873

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

1. Review · secondary evidence

   Mazdutide: First Approval.

   Shirley M · Drugs · 2025

   PMID 41028652 · DOI: 10.1007/s40265-025-02249-y

Mazdutide supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Mazdutide for sale: compare prices, sizes and forms from every tracked supplier →

Reference sources & further reading

• PubChem compound record 167312357 — chemical identity and structure.
• ChEMBL drug record CHEMBL5095358 — development stage, mechanism and synonyms.
• Wikipedia: Mazdutide — Background encyclopedia; not a primary clinical source.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles